grant
Tumor Immunology and Immunotherapy
Organization ROSWELL PARK CANCER INSTITUTE CORPLocation BUFFALO, UNITED STATESPosted 16 Jun 1997Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY2025AccountingActive ImmunotherapyAutomobile DrivingAwardBasic ResearchBasic ScienceCAR T cellsCAR modified T cellsCAR-TCAR-TsCCSGCancer CenterCancer Center Support GrantCancer PatientCancersCatchment AreaCell TherapyCellular immunotherapyChicagoClinicClinicalClinical ResearchClinical StudyClinical TrialsCollaborationsCommunitiesCommunity OutreachComplexComprehensive Cancer CenterDedicationsDevelopmentDysmyelopoietic SyndromesEducationEducation and TrainingEducational aspectsEncapsulatedEnrollmentEnsureEnvironmentEnvironmental FactorEnvironmental Risk FactorFacultyFosteringFundingFunding OpportunitiesGeneralized GrowthGoalsGrantGripsGrowthHealthHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHistoryHumanHumanitiesImmune MarkersImmune mediated therapyImmune systemImmunologic MarkersImmunologically Directed TherapyImmunologyImmunooncologyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyIncidenceInfrastructureInnovative TherapyInstitutionInterventionJournalsLeadLeadershipLength of LifeLongevityLymphoidMagazineMalignant Hematologic NeoplasmMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryMentorsMissionModern ManMolecular FingerprintingMolecular ProfilingMyelodysplastic DiseaseMyelodysplastic SyndromesMyelogenousMyeloidOat cell carcinomaOvary CancerPaperPatient CarePatient Care DeliveryPatientsPb elementPeer ReviewPhysiciansPositionPositioning AttributePre-Clinical ModelPreclinical ModelsProcessProductivityPublic HealthPublicationsQOLQualifyingQuality of lifeRecording of previous eventsRefractory Anemia with an Excess of BlastsRefractory anaemia with excess blastsResearchResearch SupportResource SharingRiskRoleScienceScientific PublicationScientistSmall Cell Lung CancerSmoldering LeukemiaSolidStrategic PlanningStrategic visionT cells for CARTargeted ResearchTestingTherapeuticTherapy trialTissue GrowthTrainingTraining and EducationTranslatingTranslational ResearchTranslational ScienceTumor EscapeTumor Immune EscapeTumor ImmunityUnderrepresented Ethnic MinorityUnderrepresented MinorityUniversitiesWorkanti-cancer immunotherapyanti-cancer researchanti-tumor immune responseanti-tumor immune therapyanti-tumor immunityanti-tumor immunotherapyanticancer immunotherapyantitumor immunitybasebasescancer clinical trialcancer evasioncancer immune escapecancer immune evasioncancer immunitycancer immunologycancer immunotherapycancer researchcancer typecare for patientscare of patientscareercaring for patientscell based interventioncell mediated interventioncell mediated therapiescell-based immunotherapycell-based therapeuticcell-based therapycellular therapeuticcellular therapychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical applicabilityclinical applicationclinical trial enrollmentcollaboration with communitiescommunity collaborationcommunity engagementcommunity-based collaborationdevelopmentaldrivingengagement with communitiesenrollenvironmental riskgraspheavy metal Pbheavy metal leadhistoriesimaging in vivoimmune cell therapyimmune drugsimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based biomarkersimmune-based cancer therapiesimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmune-oncologyimmuno oncologyimmuno therapyimmunologic therapeuticsimmunological biomarkersimmunological markersimmunology oncologyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunotherapeuticsimmunotherapy agentimmunotherapy for cancerimmunotherapy of cancerimprovedin vivo imaginginnovateinnovationinnovativeinvestigator-initiated triallung oat cell carcinomalung small cell neuroendocrine carcinomamalignancymembermolecular profilemolecular signaturemyelodysplasianeoplasm immunologyneoplasm immunotherapyneoplasm/cancerneoplasticnext generationnoveloat cell canceroncoimmunologyoncology clinical trialontogenyovarian cancerpatient populationpre-clinicalpreclinicalpreventpreventingprogramsrecruitresistance mechanismresistance to therapyresistant mechanismresistant to therapyresponsesafety assessmentsmall cell lung carcinomasmall cell undifferentiated carcinomasocial rolestemtherapeutic resistancetherapeutic targettherapy resistanttranslation researchtranslational investigationtranslational pipelinetranslational spectrumtreatment resistancetreatment trialtumor evasiontumor immune evasiontumor immune therapytumor immunologytumor immunotherapyunder-representation of minoritiesunder-represented minorityunderrepresentation of minorities
Description preview
PROJECT SUMMARY (ABSTRACT)
The Tumor Immunology and Immunotherapy Program (TII) at the Roswell Park Comprehensive Cancer Center
encompasses a comprehensive scope of immunology research, from basic mechanistic studies to clinical
applications. Our work is grounded in the understanding of harnessing the immune system to prevent and treat
patients…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click